| Supporting Access to Alcohol Use Disorder and Alcohol Withdrawal Treatment |
American Association of Addiction Medicine |
| Editorial: Challenges to Opioid Use Disorders During COVID‐19 |
American Journal on Addictions |
| Managing mental health during COVID-19 |
American Medical Association |
| COVID-19 - Infection Mitigation in Outpatient Settings |
American Society of Addiction Medicine |
| COVID-19 - Infection Mitigation in Residential Treatment Facilities |
American Society of Addiction Medicine |
| COVID-19 - Supporting Access to Buprenorphine |
American Society of Addiction Medicine |
| COVID-19 - Supporting Access to Telehealth |
American Society of Addiction Medicine |
| Recommendations on Chronic Pain Practice during the COVID-19 Pandemic |
American Society of Regional Anesthesia & Pain Medicine (ASRA) |
| COVID-19 pandemic and addiction: Current problems and future concerns |
Asian Journal of Psychiatry |
| Overdose in the context of COVID-19 outbreak |
BCCDC Harm Reduction Services |
| COVID-19: Harm Reduction and Overdose Response |
B.C.Centre for Disease Control |
| COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists |
B.C. Centre on Substance Use |
| Risk Mitigation in the Context of Dual Public Health Emergencies |
B.C. Centre on Substance Use |
| COVID-19: Responding to Opioid Overdoses in Overdose Prevention Services (OPS) and Supervised Consumption Sites (SCS) |
BC Ministry of Health |
| COVID-19 National Emergency Response |
California Bridge |
| Immediately reduce person to person contact in MAT services |
California Bridge |
| Starting Buprenorphine Outside of Hospitals/Clinics |
California Bridge |
| Virtual Addiction Counselling |
Canadian Addiction Counsellors Certification Federation |
| Supporting Harm Reduction in COVID 19 Shelter and Self Isolation (webinar) |
Canadian Alliance to End Homelessness |
| Virtual Care for Mental Health and Substance Use During COVID-19 [infographic] |
Canadian Centre on Substance Use and Addiction, Canadian Psychological Association, Canadian Society of Addiction Medicine, Mental Health Commission of Canada, The Royal |
| Methamphetamine, the Respiratory System and COVID-19 [report] |
Canadian Centre on Substance Use and Addiction |
| Methamphetamine, Cocaine and COVID-19 Health Risks [infographic] |
Canadian Centre on Substance Use and Addiction |
| COVID-19 and Impaired Driving Risks (infographic) |
Canadian Centre on Substance Use and Addiction |
| Getting Back on the Road: Relaxing of COVID-19 Measures and Impaired Driving Risks (infographic) |
Canadian Centre on Substance Use and Addiction |
| COVID-19 and Cannabis Smoking and Vaping: Four Things You Should Know [report] |
Canadian Centre on Substance Use and Addiction |
| COVID-19 and Cannabis Smoking: 4 Things You Should Know [infographic] |
Canadian Centre on Substance Use and Addiction |
| COVID-19 and Cannabis: How to Reduce Your Risk [infographic] |
Canadian Centre on Substance Use and Addiction |
| Managing Stress, Anxiety and Substance Use During Covid-19: A Resource for Healthcare Providers [infographic] |
Canadian Centre on Substance Use and Addiction and Mental Health Commission of Canada |
| COVID-19 Pandemic — National Rapid Guidance |
Canadian Research Initiative in Substance Misuse |
| Supporting people who use substances in shelter settings during the COVID‑19 pandemic |
Canadian Research Initiative on Substance Misuse |
| Telemedicine support for addiction services |
Canadian Research Initiative on Substance Misuse |
| COVID-19 - Opioid Agonist Treatment Guidance |
Canadian Society of Addiction Medicine |
| Ensuring Our Own Wellbeing as We Care for Others During the COVID-19 Crisis |
Canadian Society of Physician Leaders |
| COVID -19: Opioid Agonist Treatment Guidance |
Centre for Addiction and Mental Health |
| Sharing Experiences (prepared by partners and members) |
Correlation – European Harm Reduction Network |
| COVID-19 and people who use drugs |
European Monitoring Centre for Drugs and Drug Addiction |
| Cannabis and COVID-19 |
First Nations Health Authority |
| Alcohol Use: Risk Mitigation Strategies During a Pandemic |
First Nations Health Authority |
| Substance Use – Harm Reduction and COVID-19 |
First Nations Health Authority |
| OUD & the Emergency Department Experience During the COVID-19 Pandemic (video) |
Foundation for Opioid Response Efforts |
| Creating an Effective Telehealth Patient Experience for MOUD During the COVID-19 Pandemic (webinar) |
Foundation for Opioid Response Efforts |
| MOUD and the COVID-19 National Emergency Response (webinar) |
Foundation for Opioid Response Efforts |
| Caring for Pregnant and Parenting Women with OUD During the COVID-19 Pandemic (slides from webinar) |
Foundation for Opioid Response Efforts |
| Resources for Safer Gambling During COVID-19 |
Gambling Research Exchange Ontario |
| COVID-19 – Supporting People Requiring Opioid Dependence Treatment (ODT) |
Government of Newfoundland and Labrador |
| Syringe Services and Harm Reduction Provider Operations During the COVID-19 Outbreak |
Harm Reduction Coalition |
| COVID-19 Guidance for People Who Use Drugs and Harm Reduction Programs |
Harm Reduction Coalition |
| Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic |
Harm Reduction Journal |
| CDSA Exemption and Interpretive Guide for Controlled Substances |
Health Canada |
| Exceptional importation & sale of drugs in relation to COVID-19: Tier 3 drug shortages |
Health Canada |
| Frequently Asked Questions: Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists Prescribing and Providing Controlled Substances in Canada during the Coronavirus Pandemic |
Health Canada |
| Provincial/Territorial Class Exemptions for Supervised Consumption Site Operators |
Health Canada |
| Subsection 56(1) class exemption for patients, practitioners and pharmacists prescribing and providing controlled substances in Canada during the coronavirus pandemic |
Health Canada |
| Overdose Safety and Support During the Coronavirus Outbreak |
Homeless Services Association of B.C. |
| In the time of COVID-19: Civil society statement on COVID-19 and people who use drugs |
International Drug Policy Consortium |
| Supporting Frontline and Mental Health and Addiction Staff in the Covid-19 Environment |
International Initiative for Mental Health Leadership and International Initiative for Disability Leadership |
| COVID-19: Suggested Health Department Actions to Support Syringe Services Programs (SSPs) |
NASTAD |
| Clinical guide for the management of people with alcohol dependence during the coronavirus pandemic |
National Health Service, England |
| COVID-19 Harm Reduction COVID-19: Stay Home, Stay Safe |
New Zealand Drug Foundation |
| Statement by the UN expert on the right to health on the protection of people who use drugs during the COVID-19 pandemic |
Office of the High Commissioner of Human Rights, United Nations |
| COVID-19 and Opioid Treatment Programs |
Ohio Mental Health and Addiction Services |
| Managing patients with chronic pain during the COVID-19 outbreak considerations for the rapid introduction of remotely supported (e-health) pain management services |
PAIN: The Journal of the International Association for the Study of Pain |
| COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol |
Public Health England and Department of Health and Social Care |
| COVID19: Opioid Risk Mitigation |
Research-to-Policy Collaboration |
| Updated guidance for contingency planning for services during COVID-19 published |
Scottish Drugs Forum |
| Considerations for Crisis Centers and Clinicians in Managing the Treatment of Alcohol or Benzodiazepine Withdrawal during the COVID-19 Epidemic: March 19, 2020 |
Substance Abuse and Mental Health Services Administration |
| OTP Guidance for Patients Quarantined at Home with the Coronavirus |
Substance Abuse and Mental Health Services Administration |
| Suggestions about treatment, care and rehabilitation of people with drug use disorder in the context of the COVID-19 pandemic |
United Nations Office on Drugs and Crime |
| COVID-19 HIV Prevention, Treatment, Care and Support for People Who Use Drugs and People in Prison |
United Nations Office on Drugs and Crime |
| Suggestions about treatment, care and rehabilitation of people with drug use disorder in the context of the COVID-19 pandemic |
United Nations Office on Drugs and Crime |
| Alcohol and Opioid use in the Time of COVID-19 (webinar summary and link) |
University of British Columbia |
| UNSW Speakeasy Podcast, S05, Extra Easy Ep 1: COVID-19 & Harm Reduction Special |
University of New South Wales |
| A public health approach to withdrawal management in a pandemic |
Vancouver Coastal Health |
| Prescriber Guidelines for Risk Mitigation in the Context of Dual Public Health Emergencies |
Vancouver Coastal Health |
| Coronavirus (COVID-19): guidance for substance misuse and homelessness services (version 1) |
Welsh Government |
| Harm Reduction Guidance |
Yale Program in Addiction Medicine |
| COVID-19 et les approches favorisant l’observance des mesures de précaution et de protection auprès des personnes en situation de vulnérabilité (in French only) |
Institut national d'excellence en santé et en services sociaux |
| Le traitement du trouble lié à l’utilisation d'opioïdes (TUO) : version temporaire comprenant les mesures d'exception autorisées par Santé Canada en lien avec al pandémie de la COVID-19 (in french only) |
Collège des médecins du Québec |
| COVID-19 (coronavirus) (in French only) |
Institut national de santé publique du Québec |
| COVID-19 (in French only) |
Institut universitaire sur les dépendances et Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de-l'Île-de-Montréal |
